tbuckley/cabot-search huggingface dataset:
Iron Kinetics
Authors: WILLIAM E. BARRY
Journal: Annals of Internal Medicine (1974)

Comments1 January 1974Iron KineticsWILLIAM E. BARRY, M.D., F.A.C.P.WILLIAM E. BARRY, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-80-1-115_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In his editorial note, "Iron Kinetics in Man: New Studies with Mouse Hemoglobin," (Ann Intern Med79:271-272, 1973), Fairbanks cites the work of Dresch and Najean (1), who used mouse hemoglobin as a marker of the catabolic limb of iron metabolism in the reticuloendothelial system in man. Their conclusions are based on the belief, previously shared by others (2), including us (3), that the hemoglobin-haptoglobin complex, in small amounts, is removed by the reticuloendothelial system. Notwithstanding their reference to histologic evidence supporting this in rats (4), other studies (5, 6) of rats have clearly shown that hemoglobin coupled with haptoglobin...References1. DRESCHNA JEAN CY: Hemoglobin iron kinetics in man. Rev Eur Etud Clin Biol 17:930-942, 1972 MedlineGoogle Scholar2. KEENEJANDL WJ: The sites of hemoglobin catabolism. Blood 36:705-719, 1965 CrossrefGoogle Scholar3. BARRYTALLARIDARUSY WRB: Kinetics of release of iron from reticuloendothelial system. J Reticuloendothelial Soc 5:412-421, 1968 MedlineGoogle Scholar4. GOLDFISCHERNOVIKOFFALBALA SAA: Hemoglobin uptake by rat hepatocytes and its breakdown within lysosomes. J Cell Biol 44:513-529, 1970 CrossrefMedlineGoogle Scholar5. HERSHKOCOOKFINCH CJC: Storage iron kinetics. II. The uptake of hemoglobin iron by hepatic parenchymal cells. J Lab Clin Med 80:624-634, 1972 MedlineGoogle Scholar6. BISSELLHAMMAKERSCHMID DLR: Cellular sites of erythrocyte and hemoglobin catabolism in the liver (abstract). Blood 38:789, 1971 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1974Volume 80, Issue 1Page: 115-115KeywordsHaptoglobinsHemoglobin Issue Published: 1 January 1974 PDF DownloadLoading ...
Surveillance of ambulance dispatch data as a tool for early warning
Authors: K H Bork, B M Klein, K Mølbak, S Trautner, U B Pedersen, E Heegaard
Journal: Eurosurveillance (2006)

Early detection of disease outbreaks is essential for authorities to initiate and conduct an appropriate response. A need for an outbreak detection that monitored data predating laboratory confirmations was identified, which prompted the establishment of a novel symptom surveillance system. The surveillance system monitors approximately 80% of the Danish population by applying an outbreak detection algorithm to ambulance dispatch data. The system also monitors both regional and national activity and has a built-in, switch-on capacity for implementing symptom surveillance reporting in case of an alert. In an evaluation with outbreak scenarios it was found that decreasing the outbreak detection sensitivity from a prediction limit of 95% to one of 99% moderately reduced the time to detection, but considerably diminished the number of false alerts. The system was able to detect an increased activity of influenza-like illness in December 2003 in a timely fashion. The system has now been implemented in the national disease surveillance programme.
Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
Authors: Hossein Borghaei, David M. O'Malley, Shelly Marie Seward, Todd Michael Bauer, Raymond P. Perez, Amit M. Oza, Woondong Jeong, Mary F. Michenzie, Maurice William Kirby, Gurudatt Chandorkar, Rodrigo Ruiz-Soto, Michael J. Birrer, Kathleen N. Moore
Journal: Journal of Clinical Oncology (2015)

5558 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC comprising a FRα-binding antibody and potent maytansinoid, DM4. Methods: This Phase 1 trial is being conducted to determine safety, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, recommended phase 2 dose (RP2D) and evidence of activity of IMGN853 in pts with EOC or other FRa-positive solid tumors. As previously reported, the occurrence of ocular adverse events (AEs) was associated with peak drug exposure and pt weight. Dosing by adjusted ideal body weight (AIBW) instead of total body weight (TBW) was implemented to decrease PK variability. Two dosing schedules are being evaluated; (A) once every 3 weeks and (B) Days 1, 8, and 15, every 4 weeks. Results: Fifty nine pts enrolled to dose escalation to date, 44 (30 TBW; 14 AIBW) pts in A, 16 (AIBW) in B. RP2D for A was determined to be 6.0 mg/kg, while dose finding in B continues. Exposure to IMGN853 increased with an increase in dose in a more than dose-proportional manner indicating non-linear PK. AIBW dosing enabled better control of drug exposure, with more pts treated within a clinically relevant therapeutic window. The majority of AEs have been CTCAE grade 1 or 2, generally similar across both schedules: included GI events, ocular events, cough, fatigue, and neuropathy in > = 20% of patients. Nausea, vomiting and headache may be more common on schedule B. Diarrhea may be more common on schedule A. Preliminary evidence of clinical benefit (CB) (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) has been observed with both schedules during escalation. In A, CB was observed in 11/44 pts: 4 PRs; 2 confirmed CA125 responses; 5 SD, 2 for 10 cycles. In B, 5/15 evaluable pts had CB: 1 PR; 4 SD, 3 with confirmed CA125 response; six pts remain on study. Benefit was seen in epithelial and transitional cell ovarian cancer, endometrial cancer and NSCLC. Conclusions: With both schedules,IMGN853 demonstrates encouraging clinical activity in heavily pretreated patients during dose escalation with a manageable AE profile. A RP2D has been identified for schedule A, while schedule B continues dose finding. Clinical trial information: NCT01609556.
Secondary cytoreduction: can it be justified?
Authors: N P O'Rourke, H E Lambert
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.10.2050 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8410130 Secondary cytoreduction: can it be justified? N P O'RourkexN P O'RourkeSearch for articles by this author , H E LambertxH E LambertSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.10.2050 PDF "Secondary cytoreduction: can it be justified?." Journal of Clinical Oncology, 11(10), pp. 2050–2051© 1993 by American Society of Clinical Oncology
Arsenic and Blood Pressure: A Long-Term Relationship
Authors: Nate Seltenrich
Journal: Environmental Health Perspectives (2015)

A Long-Term RelationshipOverexposure to naturally occurring arsenic in groundwater and soil can cause a variety of cancers and has been associated with developmental effects, neurotoxicity, diabetes, and cardiovascular disease. 1 In this issue of EHP, researchers provide new evidence of arsenic's ability
Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy
Authors: Yu-Lin Su, Jen-Hung Fang, Chia-Ying Liao, Chein-Ting Lin, Yun-Ting Li, Shang-Hsiu Hu
Journal: Theranostics (2015)

A magneto-responsive energy/drug carrier that enhances deep tumor penetration with a porous nano-composite is constructed by using a tumor-targeted lactoferrin (Lf) bio-gate as a cap on mesoporous iron oxide nanoparticles (MIONs). With a large payload of a gas-generated molecule, perfluorohexane (PFH), and a hydrophobic anti-cancer drug, paclitaxel (PTX), Lf-MIONs can simultaneously perform bursting gas generation and on-demand drug release upon high-frequency magnetic field (MF) exposure. Biocompatible PFH was chosen and encapsulated in MIONs due to its favorable phase transition temperature (56 °C) and its hydrophobicity. After a short-duration MF treatment induces heat generation, the local pressure increase via the gasifying of the PFH embedded in MION can substantially rupture the three-dimensional tumor spheroids in vitro as well as enhance drug and carrier penetration. As the MF treatment duration increases, Lf-MIONs entering the tumor spheroids provide an intense heat and burst-like drug release, leading to superior drug delivery and deep tumor thermo-chemo-therapy. With their high efficiency for targeting tumors, Lf-MIONs/PTX-PFH suppressed subcutaneous tumors in 16 days after a single MF exposure. This work presents the first study of using MF-induced PFH gasification as a deep tumor-penetrating agent for drug delivery.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Noopur S. Raje, Edward A. Faber, Paul G. Richardson, Gary Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher J. Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson
Journal: Clinical Cancer Research (2016)

Tabalumab, a human mAb that neutralizes B-cell-activating factor (BAFF), demonstrated antitumor activity in xenograft models of multiple myeloma. Here we report on a phase I study of relapsed/refractory multiple myeloma patients in which the primary objective was to identify a tolerable and potentially efficacious dose of tabalumab when combined with bortezomib.Forty-eight patients were enrolled; 20 to the dose-escalation cohort, and 28 to cohort expansion in which a dose of 100 mg of tabalumab was evaluated. All patients had received either prior bortezomib or an immunomodulatory drug; the median number of prior therapies was 3. Bortezomib was administered intravenously on days 1, 4, 8, and 11 of a 21-day schedule. Tabalumab was given every 21 days for 3 cycles, then every 42 days thereafter.The most common grade 3/4 toxicities included thrombocytopenia, neutropenia, pneumonia, and peripheral sensory neuropathy. There were no dose-limiting toxicities, and the maximum tolerated dose was not reached. Pharmacokinetic data suggested serum exposure increased in a greater than dose-proportional manner up to a dose of 100 mg. Out of 46 evaluable patients, 20 had confirmed responses. The median time to progression (9 patients censored) was 4.8 months, and the median response duration (4 patients censored) was 7.2 months.A dose of 100 mg tabalumab in combination with bortezomib was well tolerated and active and is currently under further investigation. Clin Cancer Res; 22(23); 5688-95. ©2016 AACR.
Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography.
Authors: C Franzius, M Biermann, G Hülskamp, M Frosch, J Roth, J Sciuk, O Schober
Journal: Clinical Nuclear Medicine (2001)

FRANZIUS, CHRISTIANE M.D.; BIERMANN, MARTIN M.D.; HÜLSKAMP, GEORG M.D.; FROSCH, MICHAEL M.D.; ROTH, JOHANNES M.D.; SCIUK, JOACHIM M.D.; SCHOBER, OTMAR M.D., Ph.D. Author Information
Centenary Thoughts
Authors: John Lister
Journal: New England Journal of Medicine (1964)

IT is a pleasure to offer congratulations and good wishes to the Boston City Hospital and all those associated with its work on the occasion of its centenary celebrations. Hospitals throughout the ages have occupied a special place in the community that they serve. The feelings of the public toward a particular hospital are likely to vary according to individual experience. For those who have never had cause to enter it — either as patients or as visitors — the emotion may be one of fear of the unknown. For those who have been patients or visited sick relatives the . . .
Tumor Promoters in Tobacco and Cigarette-Smoke Condensate&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Fred G. Bock
Journal: JNCI Journal of the National Cancer Institute (1972)

Tumor Promoters in Tobacco and Cigarette-Smoke Condensate Get access Fred G. Bock Fred G. Bock Roswell Park Memorial Institute (New York State Department of Health), Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Pages 1849–1853, https://doi.org/10.1093/jnci/48.6.1849 Published: 01 June 1972
Case 62-1964
Authors: Daniel S. Ellis, Wallace A. Jones
Journal: New England Journal of Medicine (1964)

Presentation of Case First admission. A sixty-year-old woman was admitted to the hospital because of hematuria.Two years previously painless hematuria occurred for one day. She was well thereafter until the evening before admission, when she again passed grossly bloody urine. Eleven years before entry she had been admitted to another hospital because of vaginal bleeding; a "cauliflower tumor" of the vagina was removed, and irradiation was administered. There had been no further vaginal bleeding. For forty years she had consumed large quantities of alcohol. There was no history of fever, chills, flank pain, nausea, vomiting, jaundice, ascites or . . .
Fulminant Type 1 Diabetes
Authors: Akihisa Imagawa, Toshiaki Hanafusa, Yasuko Uchigata, Azuma Kanatsuka, Eiji Kawasaki, Tetsuro Kobayashi, Akira Shimada, Ikki Shimizu, Tetsuya Toyoda, Taro Maruyama, Hideichi Makino
Journal: Diabetes Care (2003)

OBJECTIVE— To describe the clinical and immunologic characteristics of fulminant type 1 diabetes, a novel subtype of type 1 diabetes, we conducted a nationwide survey. RESEARCH DESIGN AND METHODS—History and laboratory data, including islet-related autoantibodies, were examined in 222 patients with fulminant and nonfulminant type 1 diabetes in our hospitals in addition to another 118 patients with fulminant type 1 diabetes located outside our hospitals in Japan. RESULTS—In our hospitals, of the 222 patients studied, 43 (19.4%) were diagnosed with fulminant type 1 diabetes, 137 (61.7%) were classified as having autoimmune type 1 diabetes, and 42 were type 1 diabetic subjects who were not fulminant and did not have anti-islet antibodies. An additional 118 fulminant patients outside our hospitals were enrolled, making a total of 161 fulminant type 1 diabetic subjects (83 male and 78 female subjects; 14 children/adolescents and 147 adults) identified from all over Japan. (In 2000, the average incidence was three cases per month.) Flu-like symptoms and pregnancy were more frequently observed in the fulminant than in the autoimmune group (P &amp;lt; 0.001). In the fulminant patients, 4.8% were positive for anti-GAD antibodies and none were positive for anti–islet antigen 2 antibodies. CONCLUSIONS—Fulminant type 1 diabetes is a distinct subtype and accounts for ∼20% of the ketosis-onset type 1 diabetes cases in Japan. Flu-like symptoms are characteristic of disease onset. Metabolic derangement is more severe in this subtype than in autoimmune type 1 diabetes.
Comparision Of Different Cryoprotective Solution - Albumin Vs Autologous Plasma - Its Effect On Cell Recovery and Clonogenic Potential Of Cryopreserved Peripheral Blood Hematopoietic Stem and Progenitor Cells
Authors: Andrzej Smagur, Iwona Mitrus, Sebastian Giebel, Agnieszka Ciomber, Joanna Gliwinska, Katarzyna Panczyniak, Maria Sadus-Wojciechowska, Jerzy Holowiecki
Journal: Blood (2013)
SAT0612 Carpal Bone Cysts Resembling Erosions are Relatively Common Findings
Authors: H. Tanaka
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Cystic alterations of carpal bones are occasionally found on imaging examination of the wrist. These alterations could potentially confused as bone erosions in rheumatoid arthritis. Detection of bone erosion is very important in the diagnosis and treatment of rheumatoid arthritis, however very few studies have assessed on the cystic alterations of carpal bones. <h3>Objectives</h3> To investigate the prevalence and distributing features of carpal bone cysts. <h3>Methods</h3> We analyzed 156 three-dimensional extremity computed tomographies (CTs) on carpal bones of patients with distal radius fractures (120 women and 36 men with a mean age of 63 years). Patients with carpal bone fracture or prior arthralgia were excluded from this study. Cystic alterations on CTs were evaluated separately in each carpal bone in the sagittal, coronal and transverse planes. A carpal bone cyst was defined as a sharply marginated intraosseous radiolucent lesion (usually larger than 2 mm in size), with eccentric localization, visible in two planes. <h3>Results</h3> CTs showed carpal bone cysts in 72 (46%) out of 156 subjects. Altogether, 121 carpal bone cysts were found in the 1404 carpal bones evaluated (4 in the trapezium, 10 in the trapezoid, 21 in the capitate 5 in the hamate, 24 in the scaphoid, 35 in the lunate, 21 in the triquetrum, and 1 in the pisiform). Cystic alterations were found more often in the older subjects. Cyst size was &lt;4mm in 41% of all the cysts found, 4-6mm in 40%, and &gt;6mm in 19%. 29% of the cysts had the cortical penetration in at least one plane. Mild osteoarthritic changes with subchondral sclerosis were seen in 25% of lesions. <h3>Conclusions</h3> The distribution and frequency of cystic alterations as detected by CTs in carpal bones were identified. Cystic lesions were found frequently seen in the capitate, scaphoid, lunate and triquetrum, which also frequently show bone erosions in rheumatoid arthritis. These finding of the present study may be considered when distinguishing arthritic joints from normal joints. <h3>Disclosure of Interest</h3> None declared
SAT0389 Assessment of Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: P. Henrot, J. Foret, T. Barnetche, E. Lazaro, P. Duffau, J. Seneschal, T. Schaeverbeke, M.-E. Truchetet, C. Richez
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular (CV) burden. Different techniques have proven to be useful in determining the presence of subclinical CV disease, including endothelial dysfunction and atherosclerosis, and therefore to predict future vascular events. <h3>Objectives</h3> To determine if subclinical atherosclerosis is increased in patients with SLE compared to healthy individuals, then to compare the relevance of each technique between studies. <h3>Methods</h3> We performed a systematic search of studies published in PubMed up to June 2014, and reviewed recently-published abstracts from EULAR and ACR. Two reviewers independently screened articles, with a prespecified search strategy, to identify studies comparing rates of atherosclerosis in SLE patients versus healthy controls, using one of the following techniques: carotid intima-media thickness (CIMT), carotid plaque presence (CP) and flow-mediated dilatation (FMD). The results were pooled in a meta-analysis. Patient demographics, cardiovascular risk factors and treatments were collected. <h3>Results</h3> Out of 136 articles initially identified, 49 were selected for the systematic review. Meta-analysis included 31 CIMT, 26 CP and 15 FMD studies. Compared to healthy controls, SLE patients had a significantly increased CIMT (mean difference (MD) 0.07mm CI95% [0.05 - 0.09]), p&lt;0.05), more CP (OR 1.88 [1.52 - 2.32], p&lt;0.05) and a decreased FMD (MD -4.01% CI95% [-5.81 - -2.22], p&lt;0.05). We conducted a subgroup analysis regarding history of cardiovascular disease, which showed that in SLE patients without cardiovascular history, CIMT was still significantly increased (MD 0.06mm CI95% [0.03 - 0.09], p&lt;0.05) and FMD still decreased (MD -3.22% CI95% [-5.06 - -1.38], p&lt;0.05). There was marked heterogeneity between the studies, mainly explained by variable disease duration or organ damage in SLE, and differences in CV risk measure techniques. However, meta-analysis including only CIMT following new international recommendations showed still an increased CIMT in SLE patients but with low heterogeneity (MD 0.03mm CI95% [0.00-0.05], p&lt;0.05, I<sup>2</sup>=0%). <h3>Conclusions</h3> Patients with SLE are characterized by an increased subclinical atherosclerosis compared to healthy controls. CIMT seems to be a promising measure for CV risk evaluation, being non invasive, non radiant, and reproducible, and may be proposed as an alternative to the reliable carotid plaque evaluation and to FMD which is influenced by independent factors such as smoking. Future studies should focus on reducing the heterogeneity of these measures by using standardized procedures. <h3>Disclosure of Interest</h3> None declared
Role of myocardial revascularization in sudden cardiac death.
Authors: O'Rourke Ra
Journal: Circulation (1992)

Extensive atherosclerotic coronary artery disease is by far the most common pathological finding in patients with sudden cardiac death, and acute myocardial ischemia is often a contributing factor. Clinical trials using beta-blockers in postinfarction patients and bypass coronary artery surgery in patients with stable coronary artery disease have demonstrated a reduction in both sudden and total cardiac mortality after intervention. Information concerning the presence and extent of coronary artery disease, global and regional ventricular function, the presence or absence of ventricular aneurysms, and whether or not ischemia is inducible influences therapeutic management. Myocardial revascularization should be considered a primary therapy in patients with critical coronary artery stenosis, significant regions of myocardium at risk, and no inducible ventricular arrhythmias at electrophysiological testing. In patients with inducible polymorphic ventricular tachycardia or ventricular fibrillation, postoperative testing is essential, since only 50% will be suppressed by coronary artery surgery alone. In patients with inducible sustained monomorphic ventricular tachycardia and scars due to prior myocardial infarction, surgical revascularization alone will usually not be sufficient to prevent postoperative induction of the same arrhythmia. There are no data to support percutaneous transluminal coronary angioplasty as the sole therapy for post-sudden death patients who have inducible ventricular tachycardia or ventricular fibrillation on electrophysiological testing.
Anesthetic Management of Maxillofacial Injuries
Authors: W HAMELBERG, W C ROCHE, W R WALLACE, J B POINDEXTER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal